Back to Search
PETER BURCH, PH.D.
PH.D.
Psychologist
NPI: 1639120322Individual
Specialties, Licenses & Credentials
PsychologistPrimary
Psychologist
Code: 103T00000X
0727(NC)
Research & Publications (20)
An extracellular signal-regulated kinase 1- and 2-dependent program of chromatin trafficking of c-Fos and Fra-1 is required for cyclin D1 expression during cell cycle reentry.
PMID 15143165·Mol Cell Biol·2004
7-preclinical
Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
PMID 15176049·Prostate·2004
3-trial
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
PMID 10873066·Clin Cancer Res·2000
3-trial
Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.
PMID 11025699·J Urol·2000
3-trial
Mobile phones in hospital. Resurgence in memorial postmortem photography?
PMID 19293207·BMJ·2009
8-other
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
PMID 19380444·J Clin Oncol·2009
3-trial
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
PMID 19536890·Cancer·2009
3-trial
Stentless porcine valves in the right ventricular outflow tract: improved durability?
PMID 19211257·Eur J Cardiothorac Surg·2009
7-preclinical
A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group.
PMID 17320666·Urology·2007
3-trial
Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases.
PMID 17932892·Cancer·2007
8-other
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
PMID 16622120·J Natl Cancer Inst·2006
8-other
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
PMID 16782921·J Clin Oncol·2006
2-rct
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
PMID 16502355·Invest New Drugs·2006
3-trial
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.
PMID 16461457·Proc Natl Acad Sci U S A·2006
7-preclinical
SHP-2 activates signaling of the nuclear factor of activated T cells to promote skeletal muscle growth.
PMID 17015617·J Cell Biol·2006
7-preclinical
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
PMID 15754203·Cancer Chemother Pharmacol·2005
3-trial
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
PMID 15759136·Support Care Cancer·2005
4-observational
Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial.
PMID 15803016·Am J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3310 CROASDAILE DR, SUITE 700
DURHAM, NC 27705 - Phone
- (919) 383-8220
Quick Facts
- NPI
- 1639120322
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile